Both in Pharmaceuticals
Zymeworks vs Immunome
Over the past year ZYME returned +70.4% and IMNM returned +26.7%; their daily moves had a correlation of 0.40.
ZYME +70.4% IMNM +26.7%Growth of $1, one year, split-adjusted
| Metric | ZYME | IMNM |
|---|---|---|
| Price | $30.94 | $19.52 |
| Market cap | $2.22B | $2.30B |
| Today | +2.69% | −3.89% |
| 1 month | +20.6% | +1.1% |
| 6 months | +12.1% | −16.1% |
| Year to date | +17.5% | −9.1% |
| 1 year | +63.8% | +14.8% |
| Revenue growth (YoY) | −90.6% | −100.0% |
| Gross margin | 100.0% | — |
| Net margin | −980.8% | — |
| P/E (TTM) | — | — |
| Price / sales | 59.9× | — |
| Net cash | $270.7M | $520.0M |
| Dividend yield | — | — |
| Volatility (60d) | 47.0% | 58.0% |
| Short % of float | 12.5% | 17.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).